

Drug Utilization Review Board

Meeting Minutes

Thursday, February 13, 2020 7:15 a.m. to 8:30 a.m. Cannon Health Building Room 125

Board Members Present:

Katherine Smith, PharmD
Elizabeth Gargaro, MD
Sharon Weinstein, MD
Michelle Hoffman, MD
Jennifer Brinton, MD

Judith Turner, DVM, PharmD
Neal Catalano, PharmD
Susan Siegfreid, MD
Kumar Shah, MSc, PEng

Board Members Excused:

Eric Cannon, PharmD, FAMCP Kyle Kitchen, PharmD

Dept. of Health/Div. of Health Care Financing Staff Present:

Mohit Bhakta, PharmD

Bryan Larson, PharmD

Julie Armstrong, CPhT

Joe Busby, RPh, MBA

Ngan Huynh, PharmD

University of Utah Drug Regimen Review Center Staff Presenter:

Elena Martinez Alonso, B.S. Pharm, MSc MTSI, Medical Writer

Other Individuals Present:

Jason Bott, Lilly
Scott Burns, J & J
Walerie Gonzales, U of U
Watthew Call, UUHP
Vicki Frydrych, U of U
Lauren Health, U of U
Michelle Bice, Gilead
Stuart O'Brochta, Gilead
Valerie Gonzales, U of U
Vicki Frydrych, U of U
Cole Chambers, U of U
Joanita Lake, U of U

Meeting conducted by: Katherine Smith

- 1. **Welcome & Housekeeping:** Katherine Smith opened the meeting, announced a quorum and reminded everyone to sign the rosters. Kumar Shah was welcomed back. Conflict of Interest Disclosure Forms were requested to be signed by the DUR Board for annual DUR Board requirements. Mohit Bhakta stated today's topic will focus on ADHD medication use in children and the following month will focus on ADHD medication use in Adults to create criteria for a single prior authorization form.
- 2. **Review and Approval of January Minutes:** Michelle Hoffman made a motion to Approve the minutes from January. Judith Turner seconded the motion. All in favor, motion was passed. Sharon Weinstein and Jennifer Brinton were not present for the vote.



3. P&T Committee Update:

a. Bryan Larson stated the P&T Committee did not meet in December or January. The next meeting will be held in March to review Cystic Fibrosis Gene Therapies and the ACO annual report on methodologies for PDL will be presented.

4. ADHD Medication Use in Children:

a. Information: Elena Martinez presented peer-reviewed research regarding safety and efficacy, clinical practice guidelines with age appropriate dosing and baseline information, potential prior authorization criteria, and Utah Medicaid utilization data.

Mohit Bhakta presented recommendations including requiring prior authorization for the use of stimulant agents in patients under four years of age or for the concurrent use of three or more stimulant combinations or the use of multiple short or long acting from the same category but different chemical entity, and setting quantity limits based upon the FDA recommended maximum daily dosages.

b. Public Comment: None

- c. Board Discussion: Neal Catalano asked when would the use of a stimulant be appropriate for patient's age three and under. Elizabeth Gargaro stated she would only recommend prescribing to children in this age category who have been kicked out of preschool/daycare and already tried behavioral therapy. Elizabeth Gargaro recommended not to limit prescribing to a specific provider due to access to care issue. Use of multiple prescribers are not an issue at this time. Jennifer Brinton and Elizabeth Gargaro agree that methylphenidate is appropriate for first line use with short acting prior to long acting in most situations. Long acting may be appropriate due to short acting wearing off and having to be dosed outside the home. Sharon Weinstein feels this is already standard practice. Bryan Larson stated there have been zero claims for stimulants in children under age four in the last sixty days and no children on concurrent use of three or more stimulants. Michelle Hoffman stated requiring prior authorization for children less than age four will not accomplish overall goal if there is already little usage. Kumar Shah recommends to gather more data to develop appropriate prior authorization criteria and re-visit in the coming months. Additional information can be found by listening to the recording located here https://medicaid.utah.gov/pharmacy/drug-utilization-reviewboard/?p=DUR%20Board%20Audio%20Recordings/
- **d. Board Action:** Jennifer Brinton motioned to approve dose and prior authorization recommendations. Neal Catalano seconded. Motion to approve passed unanimously.

5. Refill Tolerance:

a. Information: Bryan Larson stated historically Medicaid's refill tolerance for opioids were too "tight" at 100% and all other medications were too "loose" at



80%. Utah Medicaid will be changing the refill tolerance for controlled medications to 85% to allow members for better access to care on weekends and holidays while preventing excess fills during the year. Ngan Huynh stated this will better align with the national average which is 85%.

- b. Public Comment: None
- c. Board Discussion: Jennifer Brinton expressed concern for limitations beyond the 80% which can already be hard at times due to a variety of circumstances. Ngan Huynh mentioned that some pharmacies are already requiring a 90% controlled substance prescription use prior to dispensing another prescription. Elizabeth Gargaro stated since many pharmacies are already requiring a refill tolerance on controlled substances at 90%, there would be little impact on patients and members. Sharon Weinstein stated prescriber burden includes watching the Controlled Substance Database carefully and prescribing with caution if aberrant drug seeking behavior is present. Additional information can be found by listening to the recording located here https://medicaid.utah.gov/pharmacy/drug-utilization-review-board/?p=DUR%20Board%20Audio%20Recordings/
- d. Board Action: No vote was held for this change.
- 6. The next meeting is scheduled for Thursday, March 12, 2020 ADHD Medication Use in Adults.
- 7. **Public Meeting Adjourned:** Jennifer Brinton motioned to close the meeting. Elizabeth Gargaro seconded the motion. Unanimous Approval.

Audio recordings of DUR meetings are available online at: https://medicaid.utali.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/